Sheridan, J. P., Zhang, Y., Riester, K., Tang, M. T., Efros, L., Shi, J., . . . Elkins, J. S. (2011). Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Multiple sclerosis, 17(12), 1441. https://doi.org/10.1177/1352458511414755
Citácia podle Chicago (17th ed.)Sheridan, James P., Ying Zhang, Katherine Riester, Meina T. Tang, Lyubov Efros, Jia Shi, Jeffrey Harris, Vladimir Vexler, a Jacob S. Elkins. "Intermediate-affinity Interleukin-2 Receptor Expression Predicts CD56(bright) Natural Killer Cell Expansion After Daclizumab Treatment in the CHOICE Study of Patients with Multiple Sclerosis." Multiple Sclerosis 17, no. 12 (2011): 1441. https://doi.org/10.1177/1352458511414755.
Citácia podľa MLA (8th ed.)Sheridan, James P., et al. "Intermediate-affinity Interleukin-2 Receptor Expression Predicts CD56(bright) Natural Killer Cell Expansion After Daclizumab Treatment in the CHOICE Study of Patients with Multiple Sclerosis." Multiple Sclerosis, vol. 17, no. 12, 2011, p. 1441, https://doi.org/10.1177/1352458511414755.